Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer

R Riehle, VP Torchilin - Cancer letters, 2014 - Elsevier
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer

G Salzano, R Riehle, G Navarro, F Perche, G De Rosa… - Cancer Letters, 2014 - infona.pl
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer

G Salzano, R Riehle, G de Rosa, VPP Torchilin… - Cancer Letters, 2014 - hal.science
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.

G Salzano, R Riehle, G Navarro, F Perche… - Cancer Letters, 2013 - europepmc.org
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

[PDF][PDF] Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer

G Salzano, R Riehle, G Navarro, F Perche, G De Rosa… - Cancer Lett, 2014 - academia.edu
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer

G Salzano, R Riehle, G Navarro, F Perche… - Cancer …, 2014 - pubmed.ncbi.nlm.nih.gov
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

[HTML][HTML] Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer

G Salzano, R Riehle, G Navarro, F Perche… - Cancer …, 2014 - ncbi.nlm.nih.gov
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer.

G Salzano, R Riehle, N Gemma, P Federico… - CANCER …, 2014 - iris.unina.it
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer

G Salzano, R Riehle, G Navarro, F Perche, G de Rosa… - Cancer Letters, 2014 - hal.science
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …

Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.

G Salzano, R Riehle, G Navarro, F Perche… - Cancer Letters, 2013 - europepmc.org
The discovery that survivin, a small anti-apoptotic protein, is involved in chemoresistance,
opens a new scenario to overcome the drug resistance in cancer. It was shown that siRNA …